September 27th 2024
A study presented at the American Academy of Pediatrics 2024 National Conference finds children with disabilities in foster care face lower permanency rates and higher mortality risks, calling for specialized support and interventions.
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Eating Disorders More Likely in Girls with ADHD
March 19th 2008Girls with attention-deficit/hyperactivity disorder (ADHD)-combined type, who have deficits in both attention and hyperactivity-impulsivity, are more likely than girls with ADHD-inattentive type or other girls to develop eating pathologies as adolescents, according to a report in the February issue of the Journal of Abnormal Psychology.
ADHD Stimulants Not Related to Drug Abuse
March 4th 2008The use of stimulant treatment in male children with attention-deficit/hyperactivity disorder (ADHD) wasn't associated with an increased or decreased risk of later substance use disorder, according to research published online March 3 in the American Journal of Psychiatry.
ADHD Stimulants Not Related to Drug Abuse
March 4th 2008The use of stimulant treatment in male children with attention-deficit/hyperactivity disorder (ADHD) wasn't associated with an increased or decreased risk of later substance use disorder, according to research published online March 3 in the American Journal of Psychiatry.
L-acetylcarnitine Improves ADHD in Fragile X Syndrome
February 20th 2008Treatment with L-acetylcarnitine may be beneficial in improving hyperactivity and social behavior in boys with fragile X syndrome who have attention-deficit/hyperactivity disorder (ADHD), according to an article published online Feb. 19 in the American Journal of Medical Genetics.
Adolescents with ADHD Need Special Attention
October 29th 2007Adolescents with ADHD are different from other patients. Impulsiveness and inattention pose bigger problems than hyperactivity, which can translate into lower medication adherence and growing behavioral problems. And adolescent girls tend to exhibit more problems than boys in the same age range.
ADHD pharmacotherapy: Prescribe with safety in mind and monitor results with vigilance
June 14th 2007The keys to optimal use of psychostimulant and nonstimulant medications for attention deficit hyperactivity disorder are careful screening of patients, appropriate dosage regulation, and?most of all?close monitoring of both positive and adverse outcomes.
Brain's fear center smaller in most severely socially-impaired males with autism spectrum disorders
January 12th 2007Researchers funded by the National Institutes of Health's (NIH) National Institute of Mental Health (NIMH) and National Institute on Child Health and Human Development (NICHD) have discovered that the brain's fear hub likely becomes abnormally small in the most severely socially-impaired males with autism spectrum disorder. New findings suggest that social fear in autism may initially trigger a hyperactive, abnormally enlarged amygdala, which eventually gives way to a toxic adaptation that kills amygdala cells and shrinks the structure, said Richard Davidson, Ph.D., and colleagues at the University of Wisconsin.
ADHD pharmacotherapy: Prescribe with safety in mind and monitor results with vigilance
December 1st 2006The keys to optimal use of psychostimulant and nonstimulant medications for attention deficit hyperactivity disorder are careful screening of patients, appropriate dosage regulation, and-most of all-close monitoring of both positive and adverse outcomes.
Transdermal delivery of methylphenidate passes a test of efficacy in ADHD
June 8th 2006New research reported at the annual meeting of the American Psychiatric Association in Toronto in May shows that Shire Pharmaceutical Group's methylphenidate transdermal system (Daytrana) appears a safe and well-tolerated alternative to OROS methylphenidate, and is equally efficacious.
ADHD study supports lower lead exposure limits
May 1st 2006A new study on potential interactions between genetic and environmental factors in ADHD suggests that current limits on lead exposure are too high. Lead exposure below the current limits allowed by Environmental Protection Agency regulations produced measurable impairment of executive functions, especially in boys, who have a specific variation in the DRD4 dopamine receptor gene.